Professional Summary
Education & Certifications
- Fellowship: UCLA Medical Center Obstetrics and Gynecology Fellowships (2005) CA
- Residency: UCLA Medical Center Obstetrics and Gynecology Residency (1999) CA
- Medical Education: University of Heidelberg (1989) Germany
-
- Board Certification: American Board of Obstetrics and Gynecology, Gynecologic Oncology (2008)
- Board Certification: American Board of Obstetrics and Gynecology, Obstetrics and Gynecology (2006)
- PhD, University of California, Los Angeles, Molecular Biology (2003)
- Residency: Ludwig Maximillians University (1992) Germany
Honors & Awards
- American Association of Cancer Research Outstanding Poster Award, Toronto, Canada, American Association of Cancer Research, Toronto, Canada (1995)
- OB/GYN Resident Teaching Award, University of California, Los Angeles (2008)
- Outstanding Podium Presentation Award, National Gynecologic Oncology Fellow鈥檚 Forum (2004)
-
- STOP Cancer Career Development Award, STOP Cancer (2008)
- Teaching Award, National Council on Resident Education in Obstetrics and Gynecology (2007)
Memberships
- Member, Society of Pelvic Surgeons (2016 - Present)
- Member, American Association of Cancer Research (1996 - Present)
- Member, American Gynecological and Obstetrical Society (2016 - Present)
-
- Member, Society of Gynecologic Investigations (2000 - Present)
- Member, American Society of Gene Therapy (2000 - Present)
- Member, Society of Gynecologic Oncology (2005 - Present)
- Member, Gynecologic Oncology Group (2005 - Present)
Administrative Appointments
- Director, Mary Lake Polan Gynecologic Oncology Research Laboratory (2013 - Present)
- Director, Stanford Gynecologic Oncology Clinical Care Program (2013 - Present)
- Director, Stanford Obstetrics and Gynecology, Division of Gynecologic Oncology (2013 - Present)
-
- Director, Stanford Clinical Research Group for Gynecologic Cancer Trials (2014 - Present)
- Director, Stanford Gynecologic Oncology Fellowship (2016 - Present)
Publications
-
IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile
Horton, H. M., Dorigo, O., Hernandez, P., Anderson, D., Berek, J. S., & Parker, S. E. (1999). IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. JOURNAL OF IMMUNOLOGY, 163(12), 6378鈥6385. -
A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature
Ghosh, K., Dorigo, O., Bristow, R., & Berek, J. (2000). A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 191(2), 212鈥215. -
Specific keynote: Immunological therapy for ovarian cancer
Berek, J. S., Dorigo, O., Schultes, B., & Nicodemus, C. (2003). Specific keynote: Immunological therapy for ovarian cancer. GYNECOLOGIC ONCOLOGY, 88(1), S105鈥揝109. -
-
Gene therapy for ovarian cancer: Development of novel treatment strategies
Dorigo, O., & Berek, J. S. (1997). Gene therapy for ovarian cancer: Development of novel treatment strategies. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 7(1), 1鈥13. -
CA125: Megadaltons of novel opportunities
Dorigo, O., & Berek, J. S. (2007). CA125: Megadaltons of novel opportunities. GYNECOLOGIC ONCOLOGY, 104(3), 505鈥507. -
HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review
Karam, A., Berek, J. S., Stenson, A., Rao, J., & Dorigo, O. (2008). HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review. GYNECOLOGIC ONCOLOGY, 111(3), 568鈥71. -
Personalizing CA125 Levels for Ovarian Cancer Screening
Dorigo, O., & Berek, J. S. (2011). Personalizing CA125 Levels for Ovarian Cancer Screening. CANCER PREVENTION RESEARCH, 4(9), 1356鈥1359. -
Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model
Dorigo, O., Shawler, D. L., Royston, I., SOBOL, R. E., Berek, J. S., & Fakhrai, H. (1998). Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model. GYNECOLOGIC ONCOLOGY, 71(2), 204鈥210. -
Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells
Dorigo, O., Gil, J. S., Gallaher, S. D., Tan, B. T., Castro, M. G., Lowenstein, P. R., 鈥 Berk, A. J. (2004). Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. JOURNAL OF VIROLOGY, 78(12), 6556鈥66. -
Anti-N-methyl-aspartate receptor encephalitis in identical twin sisters: role for oophorectomy.
Masghati, S., Nosratian, M., & Dorigo, O. (2014). Anti-N-methyl-aspartate receptor encephalitis in identical twin sisters: role for oophorectomy. Obstetrics and Gynecology, 123(2), 433鈥35. -
Increased risk and pattern of secondary malignancies in patients with invasive extramammary Paget disease.
Karam, A., & Dorigo, O. (2014). Increased risk and pattern of secondary malignancies in patients with invasive extramammary Paget disease. British Journal of Dermatology, 170(3), 661鈥71. -
Solid pseudopapillary neoplasm, pancreas type, presenting as a primary ovarian neoplasm
Stoll, L. M., Parvataneni, R., Johnson, M. W., Gui, D., Dorigo, O., & Sullivan, P. (2012). Solid pseudopapillary neoplasm, pancreas type, presenting as a primary ovarian neoplasm. HUMAN PATHOLOGY, 43(8), 1339鈥1343. -
Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development
Sullivan, P. S., Maresh, E. L., Seligson, D. B., Habeeb, O., Wadehra, M., Goodglick, L., & Dorigo, O. (2012). Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development. MODERN PATHOLOGY, 25(8), 1140鈥1148. -
Effect of PI3K/Akt Pathway Inhibition-Mediated G(1) Arrest on Chemosensitization in Ovarian Cancer Cells
Fekete, M., Santiskulvong, C., Eng, C., & Dorigo, O. (2012). Effect of PI3K/Akt Pathway Inhibition-Mediated G(1) Arrest on Chemosensitization in Ovarian Cancer Cells. ANTICANCER RESEARCH, 32(2), 445鈥452. -
Treatment outcomes in a large cohort of patients with invasive Extramammary Paget's disease
Karam, A., & Dorigo, O. (2012). Treatment outcomes in a large cohort of patients with invasive Extramammary Paget's disease. GYNECOLOGIC ONCOLOGY, 125(2), 346鈥51. -
MMPs in Ovarian Cancer as Therapeutic Targets
Karam, A., & Dorigo, O. (2012). MMPs in Ovarian Cancer as Therapeutic Targets. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 12(7), 764鈥72. -
Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy
Penner, K. R., Dorigo, O., Aoyama, C., Ostrzega, N., Balzer, B. L., Rao, J., 鈥 Holschneider, C. H. (2012). Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. GYNECOLOGIC ONCOLOGY, 124(3), 542鈥548. -
Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells
Sharma, S., Santiskulvong, C., Bentolila, L. A., Rao, J., Dorigo, O., & Gimzewski, J. K. (2012). Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 8(5), 757鈥766. -
Dual targeting of mammalian target of rapamycin and phosphoinositide 3-kinase using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma
Dorigo, O., Santiskulvong, C., Fekete, M., Karam, A., Mulholland, D., Eng, C., & Wu, H. (2009). Dual targeting of mammalian target of rapamycin and phosphoinositide 3-kinase using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. GYNECOLOGIC ONCOLOGY, 112(2), S9鈥揝10. -
Cisplatin and PI3kinase Inhibition Decrease Invasion and Migration of Human Ovarian Carcinoma Cells and Regulate Matrix-Metalloproteinase Expression
Karam, A. K., Santiskulvong, C., Fekete, M., Zabih, S., Eng, C., & Dorigo, O. (2010). Cisplatin and PI3kinase Inhibition Decrease Invasion and Migration of Human Ovarian Carcinoma Cells and Regulate Matrix-Metalloproteinase Expression. CYTOSKELETON, 67(8), 535鈥44. -
Robust In Vivo Transduction of a Genetically Stable Epstein-Barr Virus Episome to Hepatocytes in Mice by a Hybrid Viral Vector
Gallaher, S. D., Gil, J. S., Dorigo, O., & Berk, A. J. (2009). Robust In Vivo Transduction of a Genetically Stable Epstein-Barr Virus Episome to Hepatocytes in Mice by a Hybrid Viral Vector. JOURNAL OF VIROLOGY, 83(7), 3249鈥3257. -
Death from Metastatic Donor-Derived Ovarian Cancer in a Male Kidney Transplant Recipient
Lipshutz, G. S., Mihara, N., Wong, R., Wallace, W. D., Allen-Auerbach, M., Dorigo, O., 鈥 Pham, P.-T. T. (2009). Death from Metastatic Donor-Derived Ovarian Cancer in a Male Kidney Transplant Recipient. AMERICAN JOURNAL OF TRANSPLANTATION, 9(2), 428鈥432. -
Enhanced expression of L9'S mutant alpha 4 nAChR in adult mice increases the loss of midbrain dopaminergic neurons
Schwarz, S. C., Dorigo, O., Labarca, C., Berk, A. J., Lester, H. A., & Schwarz, J. (2004). Enhanced expression of L9'S mutant alpha 4 nAChR in adult mice increases the loss of midbrain dopaminergic neurons. Presented at the 8th International Congress of Parkinsons Disease and Movement Disorders, ROME,ITALY: WILEY-LISS. -
Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine
Shawler, D. L., Bartholomew, R. M., Garrett, M. A., Trauger, R. J., Dorigo, O., Van Beveren, C., 鈥 SOBOL, R. E. (2002). Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 129(1), 99鈥106. -
Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function
Dorigo, O., Turla, S. T., Lebedeva, S., & Gjerset, R. A. (1998). Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. JOURNAL OF NEUROSURGERY, 88(3), 535鈥540. -
Progress and prospects in vaccine therapy for gynecologic cancers.
Gurski, K. J., & Steller, M. A. (1997). Progress and prospects in vaccine therapy for gynecologic cancers. Oncology (Williston Park, N.Y.), 11(11), 1727-? -
Construction and characterization of retroviral vectors for interleukin-2 gene therapy
Fakhrai, H., Shawler, D. L., VANBEVEREN, C., Lin, H., Dorigo, O., Solomon, M. J., 鈥 SOBOL, R. E. (1997). Construction and characterization of retroviral vectors for interleukin-2 gene therapy. JOURNAL OF IMMUNOTHERAPY, 20(6), 437鈥448. -
Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy
Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., MERCOLA, D., Black, K. L., 鈥 SOBOL, R. E. (1996). Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 93(7), 2909鈥2914. -
COMPARISON OF GENE-THERAPY WITH INTERLEUKIN-2 GENE MODIFIED FIBROBLASTS AND TUMOR-CELLS IN THE MURINE CT-26 MODEL OF COLORECTAL-CARCINOMA
Shawler, D. L., Dorigo, O., Gjerset, R. A., Royston, I., SOBOL, R. E., & Fakhrai, H. (1995). COMPARISON OF GENE-THERAPY WITH INTERLEUKIN-2 GENE MODIFIED FIBROBLASTS AND TUMOR-CELLS IN THE MURINE CT-26 MODEL OF COLORECTAL-CARCINOMA. JOURNAL OF IMMUNOTHERAPY, 17(4), 201鈥208. -
INTERLEUKIN-2 GENE-THERAPY IN A PATIENT WITH GLIOBLASTOMA
SOBOL, R. E., Fakhrai, H., Shawler, D., GJERSET, R., Dorigo, O., Carson, C., 鈥 Royston, I. (1995). INTERLEUKIN-2 GENE-THERAPY IN A PATIENT WITH GLIOBLASTOMA. GENE THERAPY, 2(2), 164鈥167. -
INJECTION OF COLON-CARCINOMA PATIENTS WITH AUTOLOGOUS IRRADIATED TUMOR-CELLS AND FIBROBLASTS GENETICALLY-MODIFIED TO SECRETE INTERLEUKIN-2 (IL-2) - A PHASE-I STUDY
SOBOL, R. E., Royston, I., Fakhrai, H., Shawler, D. L., Carson, C., Dorigo, O., 鈥 Wilson, D. (1995). INJECTION OF COLON-CARCINOMA PATIENTS WITH AUTOLOGOUS IRRADIATED TUMOR-CELLS AND FIBROBLASTS GENETICALLY-MODIFIED TO SECRETE INTERLEUKIN-2 (IL-2) - A PHASE-I STUDY. HUMAN GENE THERAPY, 6(2), 195鈥204. -
CHARACTERIZATION OF A NEW HUMAN GLIOBLASTOMA CELL-LINE THAT EXPRESSES MUTANT P53 AND LACKS ACTIVATION OF THE PDGF PATHWAY
Gjerset, R. A., Fakhrai, H., Shawler, D. L., Turla, S., Dorigo, O., GROVERBARDWICK, A., 鈥 SOBOL, R. E. (1995). CHARACTERIZATION OF A NEW HUMAN GLIOBLASTOMA CELL-LINE THAT EXPRESSES MUTANT P53 AND LACKS ACTIVATION OF THE PDGF PATHWAY. IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 31(3), 207鈥214. -
A NON-LYMPHOMA IDIOTYPE IS INDICATIVE AND PREDICTIVE FOR B-CELL MALIGNANCIES IN AIDS
Herndier, B., McGrath, M., Abbey, N., Wang, H. T., Ng, V., Dorigo, O., 鈥 Kohler, H. (1993). A NON-LYMPHOMA IDIOTYPE IS INDICATIVE AND PREDICTIVE FOR B-CELL MALIGNANCIES IN AIDS. HYBRIDOMA, 12(5), 529鈥537. -
VALUE OF BOWEL RESECTION AND PREOPERATIVE COLOSCOPY IN OVARIAN-CANCER
Dorigo, O., Meier, W., Scheidel, P., & Hepp, H. (1993). VALUE OF BOWEL RESECTION AND PREOPERATIVE COLOSCOPY IN OVARIAN-CANCER. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 254(1-4), 966鈥968. -
LYMPHOCYTE SUBPOPULATIONS IN WOMEN WITH MALIGNANT-TUMORS IN CORRELATION WITH KNOWN PROGNOSTIC FACTORS AND AS DISEASE PARAMETERS DURING CYTOKINE THERAPY
ROMISCH, M., Bauer, F., Daponte, A., Meier, W., Dorigo, O., & Eiermann, W. (1993). LYMPHOCYTE SUBPOPULATIONS IN WOMEN WITH MALIGNANT-TUMORS IN CORRELATION WITH KNOWN PROGNOSTIC FACTORS AND AS DISEASE PARAMETERS DURING CYTOKINE THERAPY. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 254(1-4), 1091鈥1093. -
ACTIVATION OF NEUTROPHILS IN THE MICROVASCULATURE OF THE ISCHEMIC AND REPERFUSED MYOCARDIUM
Tillmanns, H., Neumann, F. J., Tiefenbacher, C., Dorigo, O., Parekh, N., Waas, W., 鈥 Kuebler, W. (1993). ACTIVATION OF NEUTROPHILS IN THE MICROVASCULATURE OF THE ISCHEMIC AND REPERFUSED MYOCARDIUM. Presented at the 2nd Symposium of the German-Heart-Institute - Coronary Endothelium and Smooth Muscle : Basic Aspects and Clinical Consequences, BERLIN,GERMANY: W B SAUNDERS CO LTD. -
A MONOCLONAL-ANTIBODY (IF7) SPECIFIC FOR HUMAN ANTI-HIV IG INDUCES APOPTOSIS AND INHIBITS CTL ACTIVITY IN CD8+ LYMPHOCYTES FROM HIV-1 INFECTED INDIVIDUALS
Muller, S., Collins, H., Brams, P., Wang, H., Dorigo, O., McGrath, M., 鈥 Kohler, H. (1993). A MONOCLONAL-ANTIBODY (IF7) SPECIFIC FOR HUMAN ANTI-HIV IG INDUCES APOPTOSIS AND INHIBITS CTL ACTIVITY IN CD8+ LYMPHOCYTES FROM HIV-1 INFECTED INDIVIDUALS. WILEY-BLACKWELL. -
NEW TECHNIQUES FOR THE STUDY OF THE CORONARY MICROCIRCULATION - IMPORTANCE OF MEASUREMENTS OF CORONARY FLOW RESERVE IN THE CLINICAL SETTING
Tillmanns, H., Neumann, F. J., Waas, W., Mall, G., Parekh, N., Tiefenbacher, C., 鈥 Kubler, W. (1992). NEW TECHNIQUES FOR THE STUDY OF THE CORONARY MICROCIRCULATION - IMPORTANCE OF MEASUREMENTS OF CORONARY FLOW RESERVE IN THE CLINICAL SETTING. CORONARY ARTERY DISEASE, 3(7), 586鈥592. -
SHORT-TERM OUTCOME IN INFANTS WITH BIRTH WEIGHTS LESS-THAN 1750-G BORN TO MOTHERS WITH HELLP SYNDROME
Gortner, L., Pohlandt, F., Bartmann, P., Terinde, R., Versmold, H., & Dorigo, O. (1992). SHORT-TERM OUTCOME IN INFANTS WITH BIRTH WEIGHTS LESS-THAN 1750-G BORN TO MOTHERS WITH HELLP SYNDROME. JOURNAL OF PERINATAL MEDICINE, 20(1), 25鈥28. -
PHARMACOLOGICAL EFFECTS ON CORONARY MICROVESSELS DURING MYOCARDIAL-ISCHEMIA
Tillmanns, H., Neumann, F. J., Parekh, N., Dorigo, O., Tiefenbacher, C., Zimmermann, R., 鈥 Kubler, W. (1990). PHARMACOLOGICAL EFFECTS ON CORONARY MICROVESSELS DURING MYOCARDIAL-ISCHEMIA. EUROPEAN HEART JOURNAL, 11, 10鈥15. -
MICROCIRCULATION IN THE HYPERTROPHIC AND ISCHEMIC HEART
Tillmanns, H., Neumann, F. J., Parekh, N., Zimmermann, R., Tiefenbacher, C., Dorigo, O., 鈥 Kubler, W. (1990). MICROCIRCULATION IN THE HYPERTROPHIC AND ISCHEMIC HEART. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 39, S9鈥揝12. -
Apoptosis of CD4+ and CD8+ cells from HIV-1 infected individuals: role of anti-idiotypic antibodies
Muller, S., Brams, P., Collins, H., Dorigo, O., & Kohler, H. (1995). Apoptosis of CD4+ and CD8+ cells from HIV-1 infected individuals: role of anti-idiotypic antibodies. Vaccine Research, Vol 4(No 4). -
Immuno-gene therapy of colon carcinoma and central nervous tumors
Sobol, R. E., Fakhrai, H., Shawler, D. L., Dorigo, O., Gjerset, R. A., Mercola, D., 鈥 Bartholomew, R. (1996). Immuno-gene therapy of colon carcinoma and central nervous tumors. In: Gene Therapy and Cancer. -
Interleukin-2 (IL-2) gene therapy with allogenic fibroblasts in the CT-26 model of murine colorectal carcinoma
Shawler, D. L., Dorigo, O., Van Beveren, C., Bartholomew, R. M., Fakhrai, H., & Sobol, R. E. (1997). Interleukin-2 (IL-2) gene therapy with allogenic fibroblasts in the CT-26 model of murine colorectal carcinoma. Oncology Reports, 4(N1). -
Gene therapy for ovarian cancer 鈥 Molecular scissors of the new millenium?
Dorigo, O., & Berek, J. S. (1998). Gene therapy for ovarian cancer 鈥 Molecular scissors of the new millenium? Journal of Gynecologic Techniques, 4. -
Synergy of transforming growth factor beta (TGF-beta) antisense and IL-2 gene therapy in the murine ovarian teratoma model
Dorigo, O., Shawler, D. L., Royston, I., Sobol, R. E., Berek, J. S., & Fakhrai, H. (1998). Synergy of transforming growth factor beta (TGF-beta) antisense and IL-2 gene therapy in the murine ovarian teratoma model. Gynecologic Oncology, (71). -
Enhanced Expression of L9'S Mutant nAChR in Adult Mice Increases the Loss of Midbrain Dopaminergic Neurons
Schwarz, J., Schwarz, S. C., Dorigo, O., Labarca, C., Deshpande, P., Gil, J., 鈥 Lester, H. A. (2006). Enhanced Expression of L9'S Mutant nAChR in Adult Mice Increases the Loss of Midbrain Dopaminergic Neurons. The Journal of the Federation of American Societies for Experimental Biology, (20 (7). -
The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells
Sharma, S., Santiskulvong, C., Rao, J., Gimzewski, J. K., & Dorigo, O. (2014). The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells. INTEGRATIVE BIOLOGY, 6(6), 611鈥17. -
Cervical cancer, version 2.2015.
Koh, W.-J., Greer, B. E., Abu-Rustum, N. R., Apte, S. M., Campos, S. M., Cho, K. R., 鈥 Scavone, J. L. (2015). Cervical cancer, version 2.2015. Journal of the National Comprehensive Cancer Network , 13(4), 395鈥404. -
Immunotherapeutic approaches to ovarian cancer treatment.
Chester, C., Dorigo, O., Berek, J. S., & Kohrt, H. (2015). Immunotherapeutic approaches to ovarian cancer treatment. Journal for Immunotherapy of Cancer, 3, 7-? -
Uterine Sarcoma, Version 1.2016 Featured Updates to the NCCN Guidelines
Koh, W.-J., Greer, B. E., Abu-Rustum, N. R., Apte, S. M., Campos, S. M., Cho, K. R., 鈥 Scavone, J. L. (2015). Uterine Sarcoma, Version 1.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(11), 1321鈥31. -
Screening cell mechanotype by parallel microfiltration
Qi, D., Gill, N. K., Santiskulvong, C., Sifuentes, J., Dorigo, O., Rao, J., 鈥 Rowat, A. C. (2015). Screening cell mechanotype by parallel microfiltration. SCIENTIFIC REPORTS, 5. -
Disseminated Intravascular Coagulation Complicating the Conservative Management of Placenta Percreta
Judy, A. E., Lyell, D. J., Druzin, M. L., & Dorigo, O. (2015). Disseminated Intravascular Coagulation Complicating the Conservative Management of Placenta Percreta. OBSTETRICS AND GYNECOLOGY, 126(5), 1016鈥18. -
Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer
Moughon, D. L., He, H., Schokrpur, S., Jiang, Z. K., Yaqoob, M., David, J., 鈥 Wu, L. (2015). Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer. CANCER RESEARCH, 75(22), 4742鈥52. -
Screening cell mechanotype by parallel microfiltration.
Qi, D., Kaur Gill, N., Santiskulvong, C., Sifuentes, J., Dorigo, O., Rao, J., 鈥 Rowat, A. C. (2015). Screening cell mechanotype by parallel microfiltration. Scientific Reports, 5, 17595-? -
Pilot prospective evaluation of F-18-FPPRGD(2) PET/CT in patients with cervical and ovarian cancer
Minamimoto, R., Karam, A., Jamali, M., Barkhodari, A., Gambhir, S. S., Dorigo, O., & Iagaru, A. (2016). Pilot prospective evaluation of F-18-FPPRGD(2) PET/CT in patients with cervical and ovarian cancer. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 43(6), 1047鈥55. -
Hemophagocytic lymphohistiocytosis as a paraneoplastic syndrome associated with ovarian dysgerminoma.
Nosratian-Baskovic, M., Tan, B., Folkins, A., Chisholm, K. M., & Dorigo, O. (2016). Hemophagocytic lymphohistiocytosis as a paraneoplastic syndrome associated with ovarian dysgerminoma. Gynecologic Oncology Reports, 17, 38鈥41. -
Cervical Cancer, Version 2.2015 Featured Updates to the NCCN Guidelines
Koh, W.-J., Greer, B. E., Abu-Rustum, N. R., Apte, S. M., Campos, S. M., Cho, K. R., 鈥 Scavone, J. L. (2015). Cervical Cancer, Version 2.2015 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(4), 395鈥404. -
Ovarian Cancer, Version 1.2016
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L.-may, 鈥 Hughes, M. (2016). Ovarian Cancer, Version 1.2016. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(9), 1134鈥63. -
Enhanced expression of hypersensitive alpha 4*nAChR in adult mice increases the loss of midbrain dopaminergic neurons
Schwarz, J., Schwarz, S. C., Dorigo, O., Stuetzer, A., Wegner, F., Labarca, C., 鈥 Lester, H. A. (2006). Enhanced expression of hypersensitive alpha 4*nAChR in adult mice increases the loss of midbrain dopaminergic neurons. FASEB JOURNAL, 20(7), 935鈥946. -
Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma
Santiskulvong, C., Konecny, G. E., Fekete, M., Chen, K.-Y. M., Karam, A., Mulholland, D., 鈥 Dorigo, O. (2011). Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma. CLINICAL CANCER RESEARCH, 17(8), 2373鈥2384. -
Interleukin-2 (IL-2) gene therapy with allogeneic fibroblasts in the CT-26 model of murine colorectal carcinoma
Shawler, D. L., Dorigo, O., VANBEVEREN, C., Bartholomew, R. M., Fakhrai, H., & SOBOL, R. E. (1997). Interleukin-2 (IL-2) gene therapy with allogeneic fibroblasts in the CT-26 model of murine colorectal carcinoma. ONCOLOGY REPORTS, 4(1), 135鈥138. -
Imaging of Tumor-Associated Macrophages in a Transgenic Mouse Model of Orthotopic Ovarian Cancer.
He, H., Chiu, A. C., Kanada, M., Schaar, B. T., Krishnan, V., Contag, C. H., & Dorigo, O. (2017). Imaging of Tumor-Associated Macrophages in a Transgenic Mouse Model of Orthotopic Ovarian Cancer. Molecular Imaging and Biology . -
Immunotherapy in ovarian cancer.
Krishnan, V., Berek, J. S., & Dorigo, O. (2016). Immunotherapy in ovarian cancer. Current Problems in Cancer. -
Vulvar Cancer, Version 1.2017 Clinical Practice Guidelines in Oncology
Koh, W.-J., Greer, B. E., Abu-Rustum, N. R., Campos, S. M., Cho, K. R., Chon, H. S., 鈥 Scavone, J. (2017). Vulvar Cancer, Version 1.2017 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(1), 92鈥120. -
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L.-may, 鈥 Hughes, M. (2016). Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network , 14(9), 1134鈥1163. -
Immunotherapy in ovarian cancer
Krishnan, V., Berek, J. S., & Dorigo, O. (2017). Immunotherapy in ovarian cancer. CURRENT PROBLEMS IN CANCER, 41(1), 48鈥63. -
Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center
Porter, J. B. (2017). Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center. Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center, 13(8), e673鈥揺682. -
Tumor associated macrophages in gynecologic cancers.
Krishnan, V., Schaar, B., Tallapragada, S., & Dorigo, O. (2018). Tumor associated macrophages in gynecologic cancers. Gynecologic Oncology. -
Cell-based immunotherapy in gynecologic malignancies.
Schaar, B., Krishnan, V., Tallapragada, S., & Dorigo, O. (2018). Cell-based immunotherapy in gynecologic malignancies. Current Opinion in Obstetrics & Gynecology, 30(1), 23鈥30. -
Uterine Neoplasms, Version 1.2018 Clinical Practice Guidelines in Oncology
Koh, W.-J., Abu-Rustum, N. R., Bean, S., Bradley, K., Campos, S. M., Cho, K. R., 鈥 Scavone, J. L. (2018). Uterine Neoplasms, Version 1.2018 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(2), 170鈥99. -
Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials
MacKay, H. J., Levine, D. A., Bae-Jump, V. L., Bell, D. W., McAlpine, J. N., Santin, A., 鈥 Kohn, E. C. (2017). Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. ONCOTARGET, 8(48), 84579鈥94. -
Hypoxic signaling in the tumor-mesothelial niche promotes collagen remodeling and ovarian cancer metastasis.
Foreman, K., Fuh, K., SorianoJAL, M., Dorigo, O., Krishnan, V., Shehade, H., 鈥 Rankin, E. (2018). Hypoxic signaling in the tumor-mesothelial niche promotes collagen remodeling and ovarian cancer metastasis. CLINICAL CANCER RESEARCH, 24(15), 57. -
Women's cancer: Advancing molecular and immunotherapy
Dorigo, O. (2017). Women's cancer: Advancing molecular and immunotherapy. CURRENT PROBLEMS IN CANCER, 41(1), 7. -
Single cell analysis of ascites macrophages in ovarian cancer
He, H. M., Yu, F. B., Quake, S. R., & Dorigo, O. (2015). Single cell analysis of ascites macrophages in ovarian cancer. CANCER RESEARCH, 75. -
Parallel microfiltration (PMF): A novel method to screen cell mechanotype
Wiedemeyer, W.-R., Qi, D., Gi, N. K., Santiskulvong, C., Dorigo, O., Rao, J. Y., 鈥 Rowat, A. C. (2015). Parallel microfiltration (PMF): A novel method to screen cell mechanotype. CANCER RESEARCH, 75. -
Comprehensive genomic profiling (CGP) of cervical squamous cell carcinoma (cSCC) to identifiy targeted therapy options.
Elvin, J. A., Bailey, M., Carneiro, B. A., Ali, S. M., Vergilio, J.-A., Palma, N. A., 鈥 Dorigo, O. (2015). Comprehensive genomic profiling (CGP) of cervical squamous cell carcinoma (cSCC) to identifiy targeted therapy options. JOURNAL OF CLINICAL ONCOLOGY, 33(15). -
M2 macrophage inhibition reverses vascular leaks that cause malignant ascites in late-stage epithelial ovarian cancer
Moughon, D., He, H., Schokrpur, S., Jiang, Z., Yaqoob, M., David, J., 鈥 Wu, L. (2015). M2 macrophage inhibition reverses vascular leaks that cause malignant ascites in late-stage epithelial ovarian cancer. CANCER RESEARCH, 75(1). -
Mutational analysis of serous ovarian cancer using Ion Torrent sequencing
Masghati, S., Dorigo, O., & Santisvkulvong, C. (2014). Mutational analysis of serous ovarian cancer using Ion Torrent sequencing. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
The role of tumor associated macrophages in ovarian cancer
He, H., Moughon, D. L., Hillerup, C., ElMasri, W., Wu, L., & Dorigo, O. (2014). The role of tumor associated macrophages in ovarian cancer. GYNECOLOGIC ONCOLOGY, 135(2), 385. -
Cell-based immunotherapy in gynecologic malignancies.
Schaar, B., Krishnan, V., Tallapragada, S., Chanana, A., & Dorigo, O. (2018). Cell-based immunotherapy in gynecologic malignancies. Current Opinion in Obstetrics & Gynecology. -
A scalable filtration method for high throughput screening based on cell deformability.
Gill, N. K., Ly, C., Nyberg, K. D., Lee, L., Qi, D., Tofig, B., 鈥 Rowat, A. C. (2018). A scalable filtration method for high throughput screening based on cell deformability. Lab on a Chip. -
Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
Koh, W.-J., Abu-Rustum, N. R., Bean, S., Bradley, K., Campos, S. M., Cho, K. R., 鈥 Scavone, J. L. (2019). Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 17(1), 64鈥84. -
Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis.
Natarajan, S., Foreman, K. M., Soriano, M. I., Rossen, N. S., Shehade, H., Fregoso, D. R., 鈥 Rankin, E. B. (2019). Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis. Cancer Research. -
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins.
Malaker, S. A., Pedram, K., Ferracane, M. J., Bensing, B. A., Krishnan, V., Pett, C., 鈥 Bertozzi, C. R. (2019). The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins. Proceedings of the National Academy of Sciences of the United States of America. -
Sentinel lymph node biopsies in endometrial cancer - practice patterns among Gynecologic Oncologists in the United States.
Renz, M., Diver, E., English, D., Kidd, E., Dorigo, O., & Karam, A. (2019). Sentinel lymph node biopsies in endometrial cancer - practice patterns among Gynecologic Oncologists in the United States. Journal of Minimally Invasive Gynecology. -
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
Malaker, S. A., Pedram, K., Ferracane, M. J., Bensing, B. A., Krishnan, V., Pett, C., 鈥 Bertozzi, C. R. (2019). The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 116(15), 7278鈥87. -
Collagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer Metastasis
Natarajan, S., Foreman, K. M., Soriano, M., Rossen, N. S., Shehade, H., Fregoso, D. R., 鈥 Rankin, E. B. (2019). Collagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer Metastasis. CANCER RESEARCH, 79(9), 2271鈥84. -
Quantitative Super-Resolution Microscopy of the Mammalian Glycocalyx.
M枚ckl, L., Pedram, K., Roy, A. R., Krishnan, V., Gustavsson, A.-K. K., Dorigo, O., 鈥 Moerner, W. E. (2019). Quantitative Super-Resolution Microscopy of the Mammalian Glycocalyx. Developmental Cell. -
Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed.
Levinson, K., Dorigo, O., Rubin, K., & Moore, K. (2019). Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, (39), e126鈥揺140. -
Omentum immune microenvironment: Metastatic niche for ovarian cancer
Krishnan, V., Raju, P. A., Vierkoetter, K., Patel, S., Youngyunpipatkul, J., Tallapragada, S., 鈥 Dorigo, O. (2018). Omentum immune microenvironment: Metastatic niche for ovarian cancer. CANCER RESEARCH, 78(13). -
ASCO 2019 meeting review.
Diver, E., Dorigo, O., & Berek, J. (2019). ASCO 2019 meeting review. Journal of Gynecologic Oncology, 30(5), e107. -
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Barkal, A. A., Brewer, R. E., Markovic, M., Kowarsky, M., Barkal, S. A., Zaro, B. W., 鈥 Weissman, I. L. (2019). CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. -
DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE(1) trial): T cell responses and tumor infiltration correlate with tumor regression.
Tanyi, J. L., Dorigo, O., Oza, A. M., Strauss, J. F., Pejovic, T., Ghamande, S. A., 鈥 Rosu, G. N. (2019). DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE(1) trial): T cell responses and tumor infiltration correlate with tumor regression. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
C-C chemokine receptor type 1 is a prognostic indicator in ovarian cancer
Chanana, A. M., Krishnan, V., Tallapragada, S., & Dorigo, O. (2019). C-C chemokine receptor type 1 is a prognostic indicator in ovarian cancer. CANCER RESEARCH, 79(13). -
THE HYPOXIC TUMOR-MESOTHELIAL NICHE PROMOTES OVARIAN CANCER METASTASIS THROUGH COLLAGEN REMODELING
Natarajan, S., Foreman, K., Soriano, M., Shehade, H., Fregoso, D., Eggold, J., 鈥 Rankin, E. B. (2019). THE HYPOXIC TUMOR-MESOTHELIAL NICHE PROMOTES OVARIAN CANCER METASTASIS THROUGH COLLAGEN REMODELING. CLINICAL CANCER RESEARCH, 25(22), 168. -
OMENTAL MACROPHAGES REGULATE OVARIAN CANCER METASTATIC COLONIZATION THROUGH THE CCL6-CCR1 SIGNALING AXIS
Krishnan, V., Tallapragada, S., Schaar, B., Chanana, A., Rinker-Schaeffer, C., & Dorigo, O. (2019). OMENTAL MACROPHAGES REGULATE OVARIAN CANCER METASTATIC COLONIZATION THROUGH THE CCL6-CCR1 SIGNALING AXIS. CLINICAL CANCER RESEARCH, 25(22), 162. -
Gestational Trophoblastic Neoplasia, Version 2.2019
Abu-Rustum, N. R., Yashar, C. M., Bean, S., Bradley, K., Campos, S. M., Chon, H. S., 鈥 Scavone, J. (2019). Gestational Trophoblastic Neoplasia, Version 2.2019. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(11), 1374鈥91. -
Sentinel Lymph Node Biopsies in Endometrial Cancer: Practice Patterns among Gynecologic Oncologists in the United States
Renz, M., Diver, E., English, D., Kidd, E., Dorigo, O., & Karam, A. (2020). Sentinel Lymph Node Biopsies in Endometrial Cancer: Practice Patterns among Gynecologic Oncologists in the United States. JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 27(2), 482鈥88. -
Quantitative super-resolution microscopy of the mammalian glycocalyx
Mockl, L., Pedram, K., Roy, A., Krishnan, V., Gustavsson, A.-K., Dorigo, O., 鈥 Moerner, W. (2019). Quantitative super-resolution microscopy of the mammalian glycocalyx. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. AMER CHEMICAL SOC. -
DPX-Survivac, a novel T-cell immunotherapy, to induce robust T-cell responses in advanced ovarian cancer
Dorigo, O., Fiset, S., MacDonald, L. D., Bramhecha, Y., Hrytsenko, O., Dirk, B., 鈥 Stanford, M. (2020). DPX-Survivac, a novel T-cell immunotherapy, to induce robust T-cell responses in advanced ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY, 38(5). -
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
Ruscito, I., Bellati, F., Ray-Coquard, I., Mirza, M. R., du Bois, A., Gasparri, M. L., 鈥 Braicu, E. I. (2020). Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. Cancer Treatment Reviews, 87, 102040. -
Minimally Invasive Surgery for Gynecologic Cancers-A Cautionary Tale.
Karam, A., & Dorigo, O. (2020). Minimally Invasive Surgery for Gynecologic Cancers-A Cautionary Tale. JAMA Oncology. -
Vulvar sarcoma outcomes by histologic subtype: a Surveillance, Epidemiology, and End Results (SEER) database review.
Johnson, S., Renz, M., Wheeler, L., Diver, E., Dorigo, O., Litkouhi, B., 鈥 Karam, A. (2020). Vulvar sarcoma outcomes by histologic subtype: a Surveillance, Epidemiology, and End Results (SEER) database review. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. -
An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins.
Shon, D. J., Malaker, S. A., Pedram, K., Yang, E., Krishnan, V., Dorigo, O., & Bertozzi, C. R. (2020). An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins. Proceedings of the National Academy of Sciences of the United States of America. -
Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1.
Krishnan, V., Tallapragada, S., Schaar, B., Kamat, K., Chanana, A. M., Zhang, Y., 鈥 Dorigo, O. (2020). Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1. Communications Biology, 3(1), 524. -
Infiltration of tumor by T cells following treatment with DPX-Survivac and intermittent low dose cyclophosphamide (CPA) leads to clinical responses in advanced recurrent ovarian cancer (OvCa).
Dorigo, O., MacDonald, L. D., Schindler, J., Bramhecha, Y., Torrey, H., Kaliaperumal, V., 鈥 Fiset, S. (2020). Infiltration of tumor by T cells following treatment with DPX-Survivac and intermittent low dose cyclophosphamide (CPA) leads to clinical responses in advanced recurrent ovarian cancer (OvCa). JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Development of Therapeutic Vaccines for Ovarian Cancer.
Chow, S., Berek, J. S., & Dorigo, O. (2020). Development of Therapeutic Vaccines for Ovarian Cancer. Vaccines, 8(4). -
Cell-based immunotherapy in gynecologic malignancies.
Kamat, K., Krishnan, V., Berek, J. S., & Dorigo, O. (2020). Cell-based immunotherapy in gynecologic malignancies. Current Opinion in Obstetrics & Gynecology. -
Abdominal FLASH irradiation reduces radiation-induced gastrointestinal toxicity for the treatment of ovarian cancer in mice.
Levy, K., Natarajan, S., Wang, J., Chow, S., Eggold, J. T., Loo, P. E., 鈥 Rankin, E. B. (2020). Abdominal FLASH irradiation reduces radiation-induced gastrointestinal toxicity for the treatment of ovarian cancer in mice. Scientific Reports, 10(1), 21600. -
An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins
Shon, D. J., Malaker, S. A., Pedram, K., Yang, E., Krishnan, V., Dorigo, O., & Bertozzi, C. R. (2020). An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins. GLYCOBIOLOGY. OXFORD UNIV PRESS INC. -
Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors.
Rahimy, E., Usoz, M., von Eyben, R., Fujimoto, D., Watanabe, D., Karam, A., 鈥 Kidd, E. (2021). Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors. Gynecologic Oncology. -
FLASH irradiation enhances the therapeutic index of abdominal radiotherapy in mice
Natarajan, S., Levy, K., Wang, J., Chow, S., Eggold, J., Loo, P., 鈥 Rankin, E. B. (2020). FLASH irradiation enhances the therapeutic index of abdominal radiotherapy in mice. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Total abdominal ultra-rapid FLASH irradiation enhances the efficacy of PD-1 inhibition in preclinical models of ovarian cancer
Chow, S., Eggold, J. T., Levy, K., Wang, J., Manjappa, R., Breitkreutz, D. Y., 鈥 Rankin, E. B. (2020). Total abdominal ultra-rapid FLASH irradiation enhances the efficacy of PD-1 inhibition in preclinical models of ovarian cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging.
Kassuhn, W., Klein, O., Darb-Esfahani, S., Lammert, H., Handzik, S., Taube, E. T., 鈥 Braicu, E. I. (2021). Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging. Cancers, 13(7). -
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Swisher, E. M., Kwan, T. T., Oza, A. M., Tinker, A. V., Ray-Coquard, I., Oaknin, A., 鈥 McNeish, I. A. (2021). Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nature Communications, 12(1), 2487. -
Long-term efficacy of megestrol acetate and tamoxifen in a recurrent adult granulosa cell tumor of the ovary.
Moon, A. S., & Dorigo, O. (2021). Long-term efficacy of megestrol acetate and tamoxifen in a recurrent adult granulosa cell tumor of the ovary. Gynecologic Oncology Reports, 36, 100770. -
Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling.
Qian, J., LeSavage, B. L., Hubka, K. M., Ma, C., Natarajan, S., Eggold, J. T., 鈥 Rankin, E. B. (2021). Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling. The Journal of Clinical Investigation, 131(16). -
Phase II Trial Evaluating Efficacy of a Fitbit Program for Improving the Health of Endometrial Cancer Survivors
Rahimy, E., Usoz, M., von Eyben, R., Fujimoto, D., Watanabe, D., Karam, A., 鈥 Kidd, E. (2021). Phase II Trial Evaluating Efficacy of a Fitbit Program for Improving the Health of Endometrial Cancer Survivors. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Prospective molecular classification of endometrial carcinomas: institutional implementation, practice, and clinical experience.
Devereaux, K. A., Weiel, J. J., Pors, J., Steiner, D. F., Ho, C., Charu, V., 鈥 Howitt, B. E. (2021). Prospective molecular classification of endometrial carcinomas: institutional implementation, practice, and clinical experience. Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc. -
Classification of molecular subtypes of high-grade serous ovarian cancer by MALDI-Imaging.
Kassuhn, W. N., Klein, O., Darb-Esfahani, S., Lammert, H., Handzik, S., Taube, E. T., 鈥 Braicu, E. I. (2021). Classification of molecular subtypes of high-grade serous ovarian cancer by MALDI-Imaging. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Abdominopelvic FLASH Irradiation Improves PD-1 Immune Checkpoint Inhibition in Preclinical Models of Ovarian Cancer.
Eggold, J. T., Chow, S., Melemenidis, S., Wang, J., Natarajan, S., Loo, P. E., 鈥 Rankin, E. B. (2021). Abdominopelvic FLASH Irradiation Improves PD-1 Immune Checkpoint Inhibition in Preclinical Models of Ovarian Cancer. Molecular Cancer Therapeutics. -
Cell-based immunotherapies in gynecologic cancers.
Lang, S. M., & Dorigo, O. (1800). Cell-based immunotherapies in gynecologic cancers. Current Opinion in Obstetrics & Gynecology, 34(1), 10鈥14. -
Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease.
Kibbi, N., Owen, J. L., Worley, B., Wang, J. X., Harikumar, V., Downing, M. B., 鈥 Alam, M. (2022). Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease. JAMA Oncology. -
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Gershenson, D. M., Miller, A., Brady, W. E., Paul, J., Carty, K., Rodgers, W., 鈥 Gourley, C. (2022). Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet (London, England), 399(10324), 541鈥553. -
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
Gershenson, D. M., Miller, A., Brady, W. E., Paul, J., Carty, K., Rodgers, W., 鈥 Gourley, C. (2022). Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. LANCET, 399(10324), 541鈥553. -
IDENTIFICATION OF POTENTIAL RESPONSE PREDICTORS TO MAVEROPEPIMUT-S (DPX-SURVIVAC), A NOVEL T CELL ACTIVATING IMMUNOTHERAPY, IN PATIENTS WITH ADVANCED RECURRENT OVARIAN CANCER
Dorigo, O., Ebrahimizadeh, W., Kennedy, B., MacDonald, L., Fiset, S., Villella, J., 鈥 Bramhecha, Y. (2021). IDENTIFICATION OF POTENTIAL RESPONSE PREDICTORS TO MAVEROPEPIMUT-S (DPX-SURVIVAC), A NOVEL T CELL ACTIVATING IMMUNOTHERAPY, IN PATIENTS WITH ADVANCED RECURRENT OVARIAN CANCER. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP. -
Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
Keunecke, C., Kulbe, H., Dreher, F., Taube, E. T., Chekerov, R., Horst, D., 鈥 Braicu, E. I. (2022). Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer. Gynecologic Oncology. -
Revealing the human mucinome.
Malaker, S. A., Riley, N. M., Shon, D. J., Pedram, K., Krishnan, V., Dorigo, O., & Bertozzi, C. R. (2022). Revealing the human mucinome. Nature Communications, 13(1), 3542. -
Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer.
Kamat, K., Krishnan, V., & Dorigo, O. (2022). Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer. British Journal of Cancer. -
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
Gershenson, D. M., Miller, A., Brady, W. E., Paul, J., Carty, K., Rodgers, W., 鈥 Gourley, C. (2022). Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. LANCET, 399(10324), 541鈥553. -
Clinical 糖心传媒 in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Vergote, I., Gonzalez-Martin, A., Lorusso, D., Gourley, C., Mirza, M. R., Kurtz, J.-E., 鈥 Bookman, M. A. (2022). Clinical 糖心传媒 in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. The Lancet. Oncology, 23(8), e374鈥揺384. -
Technetium Tc 99m tilmanocept fails to detect sentinel lymph nodes in endometrial cancer.
Reddy, R. A., Moon, A. S., Chow, S., Heilbroner, L., Howitt, B., Diver, E., 鈥 Karam, A. (2022). Technetium Tc 99m tilmanocept fails to detect sentinel lymph nodes in endometrial cancer. Gynecologic Oncology Reports, 43, 101054. -
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS)Consortium.
Glajzer, J., Castillo-Tong, D. C., Richter, R., Vergote, I., Kulbe, H., Vanderstichele, A., 鈥 Braicu, E. I. (2022). Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS)Consortium. Annals of Surgical Oncology. -
ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Glajzer, J., Castillo-Tong, D. C., Richter, R., Vergote, I., Kulbe, H., Vanderstichele, A., 鈥 Braicu, E. I. (2022). ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium. Annals of Surgical Oncology. -
Monocytes - A Promising New TRAIL in Ovarian Cancer Cell Therapy.
Chow, S., & Dorigo, O. (2022). Monocytes - A Promising New TRAIL in Ovarian Cancer Cell Therapy. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
A phase 1 open label, first in human trial to study safety and tolerability of NK-T cells combined with vvDD: An accelerated dose escalation in multiple tumor types.
Dorigo, O., Contag, P. R., Moser, J., Patel, S. P., & Frohlich, M. W. (2022). A phase 1 open label, first in human trial to study safety and tolerability of NK-T cells combined with vvDD: An accelerated dose escalation in multiple tumor types. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase 2 trial.
Dorigo, O., Oza, A. M., Pejovic, T., Ghatage, P., Ghamande, S., Provencher, D., 鈥 Fiset, S. (2023). Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase 2 trial. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Adjuvant radiation therapy in early-stage endometrial cancer with abnormal beta-catenin expression is associated with improved local control.
Hui, C., Mendoza, M. G., Snyder, J., Dorigo, O., Litkouhi, B., Renz, M., 鈥 Kidd, E. A. (2023). Adjuvant radiation therapy in early-stage endometrial cancer with abnormal beta-catenin expression is associated with improved local control. Gynecologic Oncology, 174, 42鈥48. -
Does lymph node assessment change the prognostic significance of substantial LVSI and p53 status in endometrial endometrioid carcinoma?
Hui, C., Mendoza, M. G., von Eyben, R., Dorigo, O., Litkouhi, B., Renz, M., 鈥 Kidd, E. (2023). Does lymph node assessment change the prognostic significance of substantial LVSI and p53 status in endometrial endometrioid carcinoma? Gynecologic Oncology, 177, 150鈥156. -
Aberrant nuclear 脽-catenin distribution does not prognosticate recurrences of endometrioid endometrial cancers - A retrospective single-institutional study.
Beshar, I., Moon, A. S., Darji, H., Liu, C., Jennings, M. T., Dorigo, O., 鈥 Renz, M. (2023). Aberrant nuclear 脽-catenin distribution does not prognosticate recurrences of endometrioid endometrial cancers - A retrospective single-institutional study. Gynecologic Oncology, 179, 85鈥90. -
Maveropepimut-S, an immune-educating therapy with durable clinical benefit in patients with recurrent ovarian cancer
Dorigo, O., Oza, A., Pejovic, T., Ghatage, P., Ghamande, S., Provencher, D., 鈥 Graff, J. (2023). Maveropepimut-S, an immune-educating therapy with durable clinical benefit in patients with recurrent ovarian cancer. GYNECOLOGIC ONCOLOGY. ACADEMIC PRESS INC ELSEVIER SCIENCE. -
Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis.
Somasegar, S., Reddy, R. A., Chow, S., Dorigo, O., Renz, M., & Karam, A. (2024). Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis. Gynecologic Oncology, 184, 190鈥197. -
EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).
Punekar, S. R., Hecht, J. R., Smith, C. J., Simeone, D. M., Dorigo, O., Boyd, L. R., 鈥 Molina, J. R. (2024). EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Recommended Guidelines for Screening for Underlying Malignancy in Extramammary Paget's Disease Based on Anatomic Subtype.
Kibbi, N., Owen, J. L., Worley, B., & Alam, M. (2024). Recommended Guidelines for Screening for Underlying Malignancy in Extramammary Paget's Disease Based on Anatomic Subtype. Journal of the American Academy of Dermatology. -
Presentation and Management of Highly Differentiated Follicular Carcinoma of Ovarian Origin With DICER1 Gene Variants.
Seav, S., Atiq, M., Lo, Y.-C. C., Shah, J., Dorigo, O., & Dosiou, C. (2024). Presentation and Management of Highly Differentiated Follicular Carcinoma of Ovarian Origin With DICER1 Gene Variants. JCEM Case Reports, 2(12), luae223. -
Geographical patterns in obesity and other lifestyle risk factors associated with endometrial cancer diagnosis and survival: The Women's Health Initiative longitudinal cohort
Somasegar, S., Hedlin, H., Kurian, A., Kroenke, C., Dorigo, O., & Stefanick, M. (2024). Geographical patterns in obesity and other lifestyle risk factors associated with endometrial cancer diagnosis and survival: The Women's Health Initiative longitudinal cohort. GYNECOLOGIC ONCOLOGY. ACADEMIC PRESS INC ELSEVIER SCIENCE. -
Safety and tolerability of CRX100, an NKT cell therapy combined with tumor-specific oncolytic vaccinia virus, among patients with recurrent, platinum-resistant ovarian cancer
Dorigo, O., Moser, J., Contag, P., Patel, S., & Weng, W.-K. (2024). Safety and tolerability of CRX100, an NKT cell therapy combined with tumor-specific oncolytic vaccinia virus, among patients with recurrent, platinum-resistant ovarian cancer. GYNECOLOGIC ONCOLOGY. ACADEMIC PRESS INC ELSEVIER SCIENCE. -
EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).
Spencer, K. R., Punekar, S. R., Grierson, P., Mitchell, J., Lin, Y., de Castria, T. B., 鈥 Hecht, J. R. (2025). EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Fertility-sparing treatment for atypical polypoid adenomyoma
Beshar, I., Lang, S., Dorigo, O., Howitt, B. E., Liu, C., & Karam, A. (2025). Fertility-sparing treatment for atypical polypoid adenomyoma. GYNECOLOGIC ONCOLOGY REPORTS, 58. -
Fertility-sparing treatment for atypical polypoid adenomyoma.
Beshar, I., Lang, S., Dorigo, O., Howitt, B. E., Liu, C., & Karam, A. (2025). Fertility-sparing treatment for atypical polypoid adenomyoma. Gynecologic Oncology Reports, 58, 101714. -
Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab
Somasegar, S., Sousa, B., Jairam-Thodla, A., & Dorigo, O. (2025). Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab. GYNECOLOGIC ONCOLOGY REPORTS, 58. -
Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab.
Somasegar, S., Msn, B. S., Jairam-Thodla, A., & Dorigo, O. (2025). Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab. Gynecologic Oncology Reports, 58, 101717. -
Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report.
Glover, M., Beshar, I., McHenry, A., Ding, C., Dorigo, O., Chan, E., & Shah, S. A. (2025). Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report. Case Reports in Oncology, 18(1), 473鈥479. -
Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer.
Lang, S. M., Vingopoulos, F., Beshar, I., Somasegar, S., Adams, E. V., Sasse, S. A., 鈥 Litkouhi, B. (2025). Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer. Gynecologic Oncology Reports, 59, 101738. -
Active Forms of Chemerin Are Elevated in Human and Mouse Ovarian Carcinoma.
Zhao, L., Zhou, Q., Krishnan, V., Chan, J., Sasse, S., Tallapragada, S., 鈥 Morser, J. (2025). Active Forms of Chemerin Are Elevated in Human and Mouse Ovarian Carcinoma. Biomedicines, 13(4).
-
Gene therapy for ovarian cancer: Development of novel treatment strategies
Clinical Trials
Clinical trials are 糖心传媒 studies that evaluate a new medical approach, device, drug, or other treatment. As a 糖心传媒 patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
- Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
- Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
- Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer
- Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
- Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
- A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
Practice Locations
Gynecologic Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Gynecologic Cancer Program in Palo Alto
900 Blake Wilbur Dr, Fl 1
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereStanford Women's Cancer Center Palo Alto, CA
Palo Alto, CA
Stanford Women's Cancer Center
900 Blake Wilbur Dr, Fl 1
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
糖心传媒, 糖心传媒 Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by 糖心传媒, 糖心传媒 Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of 糖心传媒, 糖心传媒 Tri- Valley, or Stanford Medicine Partners. 糖心传媒, 糖心传媒 Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Review Summary
Dr. Dorigo is consistently described as kind, caring, and professional. He is frequently praised for thoroughly explaining medical information in an understandable way and patiently answering questions, ensuring patients feel heard and confident in their care. Many appreciate his reassuring and supportive manner.
The summary was created by AI, based on recent patient reviews. Learn more
Patient Reviews
(236 reviews)
He is excellent and I'm so thankful to have him managing my care. His knowledge, experience and expertise are a godsend and blessing to me.
I really like him & feel very comfortable talking with him.
Dr.Dorigo is an excellent and wonderful Dr. I love that he explains everything so that I understand.
Very professional caring and understanding
Thorough, prepared, considerate, well-spoken, capable for physician and the team
Dr. Dorigo is a great physician, very professional, knowledgeable, and empathetic doctor. After my Spirits, my Orisas, and my husband, Dr. Dorigo and team has kept me alive since 2017!!!
I am very happy to be under Dr Doritos care. The wait for the video was long. But I know he is busy. He was very attentive to me.
I very much appreciated Dr. Dorigo's knowledge and input into my particular situation; he was extremely easy to talk to and with and I enjoyed my visit with him very much. I also greatly appreciated his willingness to conduct the appointment via a video visit.
I trust Dr Dorigo. He is straight forward with information and looks for treatment that will
be best for me. Cancer like mine is difficult
and presents challenges for stopping the advancing of metastatic disease. My Stanford team is very good and works together for me.
A 30 minute video call with Dr Durigo is likely to have changed my life. This was such a valuable appointment.
Dr Dorigo and staff very professional and caring.
Excellent Doctor. Easy to talk to
Dr Dorigo is a very nice and a great doctor!
Dr. Dorigo has been the best Oncologist. He helped me so much on my treatments and makes me understand what芒鈧劉s going on. He explained things that I can understand and very patience telling me.every details. Very nice personality and always happy that makes me comfortable.
Great!
Dr. Dorigo is an angel!
He and his team did excellent job to take care of my health.
Dr Dorigo is both knowledgeable and kind.
Dr Dorigo. Thank you for all that you do in your profession. I feel very fortunate that you and your team are my caregivers.. thank you. Lynn Nielsen
I really like Dr Doritos. He explains things very well. He also listens and to my questions and answers them so I can understand. I feel fortunate to have him as my Doctor
Dr. Dorigo is always professional and conveys deep concern about me as a patient. Always answers my questions thoroughly and explains things well.
Wonderful physician. Thorough and has a positive attitude. Answered all of my questions.
He芒鈧劉s a wonderful doctor, very thorough, personable and extremely Professional.
冒鸥鈥櫬
Dr. Oliver Dorigo is a very kind caring doctor.
Professional, but also personable
He is very patient and careful with his patients. Thank you very much to have him to be my doctor.
I think Dr Dorigo and his staff are very professional and he really cares about his patients.
Dr. Dorigo, as always, was very informative and understanding of my concerns. He is so knowledgeable and gives information that helps me make informed decisions. He is simply the best!
Very pleasant, very professional and sensitive to patient芒鈧劉s needs.
Dr Dorigo had been fantastic. He is patient and answers all questions. He makes sure you understand what is going on - especially in such an emotional field as oncology. I am so grateful to be under his care.
Excellent doctor
Dr Dorigo was SO thorough and answered all of our questions!
Dr. Dorigo was very personable and professional. I was pleased to have a potential option to my existing journey through cancer. Thank you
I have complete confidence in Dr Dorigo, his expertise, experience and manner are all excellent.
Dr. Dorigo is the best!
First time meeting him. I found him very helpful and reassuring.
Dr. Dorigo is so kind and extremely informative. He is patient with questions and has thorough and understandable explanations for all things medical. He is an excellent practitioner and teacher. I respect him and his opinions very much.
Very experienced and knowledgeable Doctor
Always thorough in providing information
He is very easy to talk to, he made me feel comfortable, he was professional, and personable. He's a great doctor. I had complete faith in him. I wish all doctors were like him. He also informed me about everything.
Dr. Dorigo did not make me feel rushed and patiently answered all my questions thoroughly. I was glad that he showed me a picture from surgery and explained what I was seeing.
Dr. Oliver Dorigo is an excellent surgeon, doctor and he cares about his patients.
Do Dorigo is friendly, a good listener, a great 糖心传媒er, thorough, professional and open. I am grateful to be in such good hands!
Oliver Dorigo is an outstanding physician. He always takes the time to answer all questions, and never makes you feel rushed. He is very thorough and leaves me feeling confident that I am indeed receiving the best health care at Stanford.
Dr. Dorigo is very empathetic to my health ordeal, and I truly trust his medical decisions. He's saved me twice before.
Dr. Dorigo is extremely helpful and communicative. He is excellent at what he does and he is caring.
Dr. Dorigo is a very kind and considerate Surgeon/Oncologist. He speaks slowly and explains things thoroughly. He asks if I have questions and always answers them completely. I trust him completely with my
health issues.
He comes across has knowledgable, and a compassionate doctor. He is a good listener.
I think I just did that on the last memo.
However, while Dr D has been my doctor and he recommended my prognosis medicine to take, he is not a magician and can芒鈧劉t make magic happen for cancer patients, ,but he is always a student learning about these new drugs and helping people that want to live almost gives you a God complex. I would feel like that if I can help someone have more life. He has done that for me. For my family. For my future. I appreciate him and his team for all their help when I needed it. Dr D is amazing and to me he is my God. I wish and hope he always can help people forever. Today is a good day. Thank you Dr D for helping me!
I think he has told me he does a lot of advicacy for the cancer drugs so he does know what he is talking about. I芒鈧劉m rambling on芒鈧. Sorry. Thank you again!!
Dr. Dorigo answered all my questions and was positive about my recovery and test results. It has been a great experience having him as my doctor for this issue.
Dr. Dorigo is one of the best physicians I have ever had.
Dr Dorigo is an excellent doctor whom I have entrusted my care with him for multiple abdominal procedures for many years. Our conversations have been very comfortable knowing he has his best interest in helping me resolve or cope with the issues st hand. I admire him fir his professionalism in extending the expertise of other doctors should it become necessary.
Despite his long hours at the hospital, I am very grateful that he extends his time to contact family/friends "outside" of his normal hours. We are very grateful for his dedication to help the patient and family members know what has transpired or the future plans of what may entail.
Thank you Dr Dorigo and staff for your utmost care you have provided to us throughout these years. Our deepest gratitude and Aloha....
He芒鈧劉s very nice to work with, and I trust his judgment.
Dr Dorigo answered all of my questions and was very personable and professional.
I would highly recommend Dr. Dorigo to anyone needing his specialized care. He was and is outstanding. Many thanks to him and his team for taking such good care of me and relieving my husband芒鈧劉s concerns throughout this procedure.
I am very thankful for the care and expertise provided by Dr. Oliver Dorigo. I talked to many doctors from other hospitals before my Stanford visit. Dr. Dorigo was the first doctor that was able to answer my questions and was willing to complete my complex surgery. My surgery results are better than what I expected. I can't thank him enough.
Dr. Dorigo is great. He took time to explain my options. Genuinely cared about my well being.
He explained everything very clearly and answered all my questions and offered more time if I had other questions. Overall an excellent visit.
Excellent sensitive brilliant doctor whom I deeply respect.
Dr Dorigo is an amazing doctor. I feel very lucky to have his help and expertise. I have all the confidence in his care.
Dr Dorigo gives me good support, and hope, about moving forward with treatment because of the good results I had experienced.from my first treatment. I felt seen, heard and confident with his treatment knowledge and direction.
He is direct and clear in his communication.
I really appreciate Dr Dorigo and being his patient.
I really like him as a doctor and trust his advice.
Dr. Dorigo is an amazing and wonderful doctor!
I was referred to him by my gynecologist and he trated me like I was one of his long time patients. Everybody in Stanford make me feel welcome and explained all the process from every step of the way to my surgery. He has alot of experience and he gives you and answers all the questions takes his time.
Dr. Dorigo is one of the best doctors I've ever encountered.
He is excellent! Listens and has a plan.
Kind, patient, knowledgeable and explains things well.
Truly am so grateful for Dr. Dorigo and his staff. I wish that all of my medical needs could mirror Dr. Dorigo芒鈧劉s empathy and care.
Dr. Oliver Dorigo is an amazing, caring doctor who takes the time to listen to you. Grateful for Dr. Dorigo!
The staff was professional and warm and attentive. Dr. Dorigo is the best doctor I have ever had the pleasure of working with. This is what world class healthcare feels like!
Dr. Dorigo is an excellent physician that is extremely knowledge.
He listens to my questions and provides thorough responses.
He includes me in the discussion and decision process.
I have a complex medical issues/status and he is aware of the issues and is apprised/aware of my other Stanford providers.
Wonderful doctor - thorough, listens carefully, explains options
He is a wonderful dr and answered all my questions thoughtfully.
Dr. Dorigo is excellent doctor. He listens and takes time to explain everything to you. I appreciate Dr. Dorigo!
I highly recommend Dr. Dorigo. Very knowledgeable, compassionate and a.great communicator.
Dr Dorigo is a fabulous doctor. He is the tops in his field but is able to explain things carefully for a patient. Dr Dorigo has literally saved my life.
Dr. Dorigo takes time to ecplain everything. He is very kind caring doctor, and excellent surgeon. My surgery went well and I am grateful and thankful to Dr. Dorigo. He is very thorough and has asked pathology to recheck prior leep samples to determine tumor size which will then determine if radiation treatment will be necessary. I appteciate his due diligence.
He was quick thinking, very pleasant and patient. He spoke to me the entire time himself, as opposed to an assistant. Explained the procedure and answered all questions I had. I feel as though I'll be in very competent hands when I have this procedure done by him.
Susan Lang and Dr Oliver Dorigo were amazing and gave me peace and calmness by talking to me explanibg my cancer and next step process. Amazing! Grateful and thankful to have them taking care of me!
Such compassionate芒鈧.. Dr Dorigo is the best! Compassionate, Knowledgeable, Respectful and just a very nice person. Thank you Stanford for enabling him to care for your patients.
Excellent doctor.
Dr. Dorigo is an excellent doctor! I am very happy to have been treated by Dr. Dorigo. He is an excellent listener and cares about the patient.
Dr. Dorigo is an excellent clinician: patient, kind, great bedside manner, never rushed me, great listening skills, humble, had clear explanations. I would definitely return, if needed, or recommend him.
Dr Dorigo is an excellent doctor and top in his field. The issues are complex and sometimes I needed explanations. I think I person would have been better
Very helpful video visit.
Following our conversation, I realized we didn't talk about the fact that I do not have the BRCA mutation, and I wonder if that would limit my ability use Zejula.
Thanks
Cheri
Dr. Dorigo was incredibly knowledgeable and compassionate. I feel extremely grateful to have such good care.
Knowledgeable, accomplished, excellent provider. Provides thorough responses and analysis. Listens and allows for patient questions and input.
Profoundly amazing Physician in every respect!!!
Very Nice
He listened to my concerns and reviewed notes from another doctor I am seeing that referenced a possible solution to the medical condition they are treating me for. I thank him for that.
I feel very fortunate to have been in the care of Dr. Dorigo and his entire team. My experience has been superlative.
Dr Dorigo had a very detailed explanation about my condition now. He is terrific !
Dr. Dorigo is outstanding. Expert care, empathic and educates the patient.
Very happy with Dr Dorigo芒鈧劉s care. I feel he has my best interest in my care. I feel fortunate to have him as my care provider.
Personable, thorough, did not rush, answered questions well.
He is very professional and Knowledgeable with Nice Heart and Kindness Attitude. There is no words can Express my GRATEFULNESS.
God bless him .
Dr Dorigo is so personable, professional, and reassuring. I feel so fortunate to have found him for my treatment. His assistant, Becky, and his staff are all attentive, professional, and all around great!
Dr. Dorigo is an excellent surgeon, and I feel so blessed that he is the one who did my surgery.
Dr. Dorigo and staff are empathic, informative and factual.
Team is great love them
Dr Dorigo is spectacular. Incredibly knowledgeable, kind, and empathetic.
Best Dr. in the world!
Dr Dorigo is awesome. He芒鈧劉s an excellent doctor. And very caring and patient. Did not rush through the appointment.
Explains thoroughly, answers questions, shows images and results.
He is the very best芒鈧..especially since he saved my life!
Dr Dorigo was extremely informative and thorough., eager to answer questions, and arrange for follow-up.. Staff very professional.
Dr. Dorigo and staff are outstanding.
Dr. Dorigo is extremely caring, kind, patient, compassionate, knowledgeable and professional. He and his team make me feel that I am in good hands. They seem to be on top of everything and I truly appreciate the professionalism.
Dr. Dorigo is an exceptional care provider
Dr. Dorigo stands out in how he answers questions completely and provided me more detailed information and assurances that I芒鈧劉ve ever had from a physician during a difficult time. If he is your doctor, you won芒鈧劉t be disappointed. Knowledgeable and thorough. The best!
We love Dr Dorigo and the efficiency of Stanford
He was very friendly and professional. He and Ashley Wood answered all my questions.
excellent doctor, not rushed & explained things well
He is superb. I have already recommended him to two fellow ovarian cancer friends.
He is an excellent surgeon & oncologist.I trust him explicitly.
Dr. Dorigo is the very best.
Lucky to have you in charge of my care
Dr. Dorigo and all the staffs are wonderful! They really care about their patients and support me in every way they can. I really appreciate them!
I appreciate the care and concern shown to me by Dr. Dorigo! His team was present and so helpful in obtaining recent diagnostics done outside of Stanford that helped guide the treatment plan for me.
Excellent
Absolutely. Dr. Dorigo is excellent!
I believe he is a wonderful, caring Doctor & surgeon & has a great staff.
It is obvious that he is working very hard and has brought inother to help make a plan for treatment
Yes芒鈧e is a Saint.
I am so blessed that I have been referred to
Dr Oliver Dorigo. Though today was only the 1st meeting which I had with him, however, I could already feel his precision in his
recommendations and judgements.
A cancer patient like me needs
a doctor like him who can give me accurate direction for my cancer journey.
Doctor Doritos is a caring and excellent doctor. I drive 4 hours to have him as my doctor/surgeon.
He listened and was honest about what he could answer and what he couldn't. Made time for my questions and was patient.
He is a very knowledgable and compassionate doctor. I trust his opinion very much and highly recommend him.
I like Dr. Dorigo and appreciate his knowledge and professional excellence on my behalf. My scheduled appt. was about 45 minutes late, with me being unsure I芒鈧劉d done everything right to connect, so that was unsettling, but
I芒鈧劉m sure that was out of his control. It would have been easier for me if he had removed the face mask so I could better understand him. And then knowing his part regarding the needed referral could be better understood so I can know how I proceed.
Dr. Dorigo and his team are the best. I can't be happier with the care I received from him and his team. Thank you again!
He is an excellent doctor
Thank you for making my journey so comfortable, I did feel like i was important and that you care.
I can芒鈧劉t remember ever meeting a nicer doctor. Very professional, yet very warm. I feel very blessed to have such a knowledgeable doctor in charge of my care.
Dr Dorigo is a truly exceptional clinician. He listens, he considers options, he芒鈧劉s highly knowledgeable and he芒鈧劉s encouraging. He always makes me feel like I matter and that my stage IV ovarian cancer is being treated appropriately and with consideration for my quality of life. I appreciate him immensely.
Dr. Dorigo and the staffs are amazing! Thank you!
Dr. Dorigo has been supported me since day one until present. He understands the seriousness of my disease. He explained treatments to me that I understood very clear. He gives detailed informations of options about my treatments. I would like Dr. Dorigo to continue helped in my treatments.
He芒鈧劉s a very good Oncologist that I want to keep treating me. Thank you
Dr. Dorigo is a wonderful doctor. He very helpful, experienced, kind, explained my condition very well, answered my questions, gave me options, etc. I芒鈧劉m very grateful for his help.
Very thorough and articulate. I felt heard and valued in the process
Extremely easy to talk to, thorough, reassuring.
Amazing Doctor!
Knows how to connect and build relationships.
Good listener.
Dr Dorigo is very warm, extremely well prepared and helpful about any questions about any aspect of my medical care 芒鈧 meaning he treats the entire person not just a body part
He芒鈧劉s accessible and completely transparent respecting his patient芒鈧劉s intelligence and time
Dr. Dorigo was very kind and clear. I felt he really listened to me and his explanations were easy to follow.
Outstanding individual. Grateful that he is my surgeon.
I trust him and know he has my best interest at heart and will take care of me.
Sent a letter to David Entwistle conveying my sincere gratitude for the care received from Dr. Oliver Dorigo and his staff.
Dr. Dorigo & his staff (especially Becky) are amazing.
Dr. Dorigo was informative positive and knowledgeable. I enjoyed his enthusiasm about the outcome of my surgery.
Dr. Dorigo spent plenty of time explaining and describing where we were in treatment. He listened to me and addressed all questions. He is the best doctor and I am thrilled he is handling my care.
Follow ups to cancer surgery & chemo - excellent, caring but still professional care. 5 star in all ways!!
The care provider advisor explained possible after side effects after the surgery and explained what could and advised me who and what to do afterward. He also told me how to take care of area around incision.
Excellent, detailed.
Excellent care.
Dr. Dorigo is amazing. He is incredibly knowledgeable, he explains everything very clearly. I feel I have the best care possible. He is kind, compassionate & has a good sense of humor.
I have trusted Dr. Dorigo with my life I came in very, very sick and he has help me a lot.
It was important that I get in to see Dr. Dorigo to discuss some current issues with my health. He was able to see me on short notice and spent a good deal of time having a discussion with me regarding the clinical trial I am currently on and a plan moving forward. He was very thorough in explaining everything to me.
Dr. Dorigo is highly recommended!
Dr. Dorigo is absolutely awesome! He was very thorough in explaining everything. Answered most of my questions before I even asked them, then patiently answered the rest.
Dr. Dorigo is an excellent physician with an extensive clinical & 糖心传媒 interest in the rare cancer I've had. I self referred myself after extensive 糖心传媒 to find and expert in the field & was glad I did so.
I like Dr. Dorigo very much.
Dr. Dorigo was superb! I will be switching my care over to him and Stanford after July!
Very good experience w/Dr. Dorigo. Like his bedside manner, does help translate in more understandable words. Most of the ONC Gync. is very complicated, and he was great!
I like & trust Dr. Dorigo.
Dr. Dorigo is thoroughly brilliant, focused on my condition, asks questions & listens.
Amazing! Dr. Dorigo is SO caring & extremely bright and dedicated. His calm, confident demeanor always put me at ease.
Dr. Dorigo & the assistant (who collected my info & Q's before doctor came in) were both courteous & thorough answering my Q's. I was there for a 2nd opinion & left confident that I had info I needed to decide on treatment course.
Dr. Dorigo was very thorough a very accommodating. He wasn't rush & was very receptive & encouraging. He was excellent. Dr. Torino - was very good as well.
A wonderful doctor, very happy with him!
Dr. Dorigo is an excellent surgeon & physician.
Expected 10 minutes so 20 minutes exceeded expectations. He was kind to show me my CT images. Dr. Dorigo speaks fast with an accent, is sometimes hard to understand.
I have had bad experiences with doctors & hospital staff before. However, I don't have 1 bad thing to say about Stanford.
Exceptional in every way!
This was one of the best dr. experiences I have ever had in a really terrible situation. He gave me hope again.
Good.
Very professional doctor, nurse practitioner, and nurse.
Excellent explanation of problem & care of it.
The doctor made me feel relaxed and not as stressed.
I couldn't ask for a better or more skilled doctor!
I have full confidence that Dr. Dorigo is exceptionally knowledge re: My condition while conducting the appointment in a very caring, attentive manner.
I have been a cancer patient under the care of Dr. Dorigo for four years and have received excellent care.
Dr. Dorigo was excellent - he explained things thoroughly & patiently; took time answering my questions & respond to my concerns; and he had an all-around friendly & confidence-instilling manner.
I feel blessed because God put on my path a doctor like Dr. Dorigo. Finally someone answered my questions. Dr. Dorigo is such an amazing doctor may he be blessed with many years of practicing medicine. This world needs doctors like him.
Dr. Dorigo was very nice and informative.
Has a hard time staying focused! Never pertinent information to issue.
Dr. Dorigo was incredible! He's very knowledgeable, very good at explaining things he spent plenty of time with me and listened carefully to my question.
Dr. Oliver Dorigo is the most wonderful doctor in this world. He saved MY LIFE!! Thank you Dr. Dorigo.
This was a referral consultation for a second opinion. Dr. Dorigo was familiar with my file from Kaiser and was prepared with a number of suggestions and next steps. The team was respectful and helpful.
Dr. Dorigo and Arthie (NP) were both very cordial spent sufficient time with me, and answered my questions.
This care team is highly knowledgeable and responsive. I was extremely impressed. Received answers to health questions my internist in Monterey did not accurately answer.
Dr. Dorigo spent ample time with me, & answered all questions & concerns.
I feel blessed & be under Dr. Dorigo's care.
Dr. Dorigo's (his) MA & NP were present during the appointment to take notes and collaborate.
Dr. Dorigo - excellent!
I am sure he is a qualified dr. but for me - he has no bedside manner. He seeing rushed, always in a hurry. Not a favorite of mine.
Dr. Dorigo did an excellent job of explaining my options. I will be getting chemo @ St. Mary's in SF, but overall treatment will be directed by Dr. Dorigo.
Excellent service.
If I have waited some time, I should understand, that my specialist doctor can be very busy attending an urgency & serious delicacy of a patient.
Dr. Dorigo has a wonderful manner about him. He also explained everything in details we fully understood. Answered all our questions. Everyone was very helpful.
He is rushed. No bedside manner. I drive 35 miles one way to go to Stanford. He spends about one minute with me. Sometime I think it is a waste of time.
I highly recommend Dr. Dorigo. He is highly skilled, compassionate & caring.
My specialist Dr. Dorigo is eminent, respectful, friendly, comprehensive and courteous.
The doctor was very gentle-thanks!
I saw Dr. Dorigo for a 2nd opinion. Very compassionate; explained to well & answered all my questions. I would highly recommend this gynecologist.
Excellence service.
Women's Cancer Center, and Dr. Dorigo's entire team, are doing a commendable job.
The fellow Dr. Swanson & Dr. Dorigo make a good team. Dr. Swanson spent a lot of time with me & had a lot of good explanations about things. Dr. Dorigo is short & to the point & also had helpful input.
Dr. Dorigo and his resident were very kind. I appreciate the gentleness with which he performed my pelvic exam and his willingness to discuss.
He is by far the best doc I have ever seen. Brilliant, humble, kind, loving & compassionate.
The staff is fast in answering a question and with good treatment.
Dr. Dorigo was GREAT! His front office staff are a poor reflection on how amazing him and his nursing staff are.
I have full confidence in Dr. Dorigo.
Dr. Dorigo is the best!
Great.
To me the doctor attended me well despite that he would explain in Spanish.
Have total confidence in Dr. Dorigo.
May God bless the hospital of Stanford & all its personnel, for the good humanity.
Dr. Dorigo explained things well & didn't make us feel rushed. He instilled much confidence.
Very interested doctor in my health and so that my treatment be efficient.
From a pt.'s perspective Dr. Dorigo is one of the most outstanding physicians I've been treated by (and I'm a nurse). I was afraid I was going to be given a devastating diagnosis, and he was not only clinically stellar, but kindly and professionally demonstrated that he understood the stress I was feeling, and really moved the treatment along quickly! I was most grateful!!!
Very happy with Dr. Dorigo. He seems like he really cares about you as a person.
Good.
Dr. Dorigo is excellent. Very happy to be his patient.
This was a second opinion, the entire staff was very helpful and considerate. I was VERY pleased with the visit.
Everything was perfect.
Lab results where not given to me until I e-mailed thru "Myhealth". So my concern level was heightened.
Dr. Dorigo is the most caring and intelligent doctor I have ever had! Thank you Dr. Dorigo.
Dr. Dorigo is an amazing doctor, very caring, knowledgeable and friendly!
Follow through post appt. has been disappointing. No one has done what they said other than order tests but leaving coordination to me when told otherwise.
Dr. Dorigo is an excellent doctor. I like the way he treats me as a patient.
I love him.
I liked that both Dr. Dorigo and his nurse called the next day after surgery to check on my well-being.
Dr. Dorigo is the most caring and intelligent doctor I encountered throughout my cancer journey. He is the biggest blessing to me throughout this journey!
Dr. Oliver Dorigo went above and beyond with patience and understanding with me as I completely emotionally, fell apart after my diagnosis. He took more time than he should have.
Good experience.
I did my "homework" on Dr. Dorigo before my appointment and was impressed but once I met him - I knew I was in excellent "hands".
He is always attentive and willing to listen & help.
Utmost respect for Dr. Dorigo! Knowledgeable, caring, shows concern, genuine & thorough.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone:听1-866-742-4811
Fax: 650-320-9443
Monday鈥揊riday, 8 a.m.鈥5 p.m.
Fax: 650-320-9443
Monday鈥揊riday, 8 a.m.鈥5 p.m.
糖心传媒 provides comprehensive services to听refer听and听track patients, as well as the latest information and news for physicians and office staff.听For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
听
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records